Table 4.
Characteristics of the included studies which employed PSMA radioligands in breast cancer.
| First Author and Year | Type | Country | N. Patients | Tracer | Histopathological SubType (N. Patients) |
Clinical Setting (N. Patients) |
Analysed Lesions | Comparator |
|---|---|---|---|---|---|---|---|---|
| Sathekge 2017 [46] | Prospective | South Africa | 19 | 68Ga-PSMA-11 (I) | 13 ductal 2 lobular 1 neuroendocrine differentiation 3 unknown |
9 staging 5 restaging for local recurrence 5 restaging for distant metastases |
81 | CT bone scan 18F-FDG PET/CT |
| Medina-Ornelas 2020 [47] | Retrospective | Mexico | 21 | 68Ga-PSMA-11 (I) | 4 luminal A 4 luminal B Her2+ 2 luminal B Her2- 5 triple negative |
Staging of locally advanced and metastatic BC | 127 | 18F-FDG PET/CT |
PET: positron emission tomography, CT: computed tomography, PSMA: prostate-specific membrane antigen, FDG: fluorodeoxyglucose, I: imaging.